Costa rica launches registry to see how new psoriasis drugs work in real life
NCT ID NCT07448402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational registry will follow 50 patients with psoriasis or psoriatic arthritis who are receiving IL-23 inhibitors (guselkumab or risankizumab) as part of their routine care in Costa Rica. Researchers will track how well the drugs improve skin and joint symptoms and quality of life, as well as any side effects. The goal is to understand how these treatments perform in everyday practice, not just in controlled studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL-23 inhibitors (guselkumab and risankizumab)
What this could lead to
If successful, this registry could provide real-world evidence on how well IL-23 inhibitors work and how safe they are for psoriatic disease patients in Costa Rica.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or missing data. It is also small (50 participants) and limited to one country.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caja Costarricense del Seguro Social
San José, Provincia de San José, 40901, Costa Rica
Contact Phone: •••-•••-•••• Email: •••••@•••••